Treace Medical Concepts, Inc.

TMCI • Medical - Devices

$4.81

▼ -0.07 (-1.43%)

Precio actual

ResultadosÚltimo reporte: 30 jun 2026

PERFIL EQUILIBRADONeutralConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Perfil mixto. La empresa no es necesariamente mala, pero la valoración, el crecimiento o el balance todavía no justifican una señal más fuerte.

Capitalización

$312.89M

Crecimiento

27.8%

Flujo de caja

0/5

Tendencia

Negative

Evidencia

Crecimiento positivo de ingresos · 17.9%Nivel de deuda manejable · 0.16Liquidez saludable · 4.31Rentabilidad débil

Datos financieros hasta: 30 jun 2026, 12:00 a.m. UTCÚltima actualización de earnings: 30 jun 2026, 12:00 a.m. UTCÚltima actualización del perfil: 9 ago 2026, 12:12 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$4.81

Change-1.43%

Shares Out65.05M

Market Cap$312.89M

Enterprise Value$280.36M

52W Range1.17 - 7.78

Beta1.38

P/E-5.26

P/S1.52

P/B4.62

P/FCF-12.49

EV/Sales1.37

Price$4.81

Change-1.43%

Shares Out65.05M

Market Cap$312.89M

Enterprise Value$280.36M

52W Range1.17 - 7.78

Beta1.38

P/E-5.26

P/S1.52

P/B4.62

P/FCF-12.49

EV/Sales1.37

EV/EBITDA-5.77

EV/FCF-11.19

Earnings Yield-19.02%

FCF Yield-8.00%

Dividend Yield0.00%

Gross Margin79.81%

Oper. Margin-25.46%

Profit Margin-27.74%

Debt/Eq0.16

Current Ratio4.31

Quick Ratio3.13

Revenue 5Y27.83%

Target$8.60

Target Upside78.79%

Target Median$6.50

Target Range3.00 - 16.00

Volume879.95K

Avg Volume734.25K

EPS Surprise0.03

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

22/100

Fortaleza financiera

Deuda, caja, estabilidad

76/100

Potencial de crecimiento

Ingresos y expansión

95/100

Atractivo del precio

Barata o cara hoy

92/100

Por qué este puntaje▼

Crecimiento positivo de ingresos · 17.9%Nivel de deuda manejable · 0.16Liquidez saludable · 4.31Rentabilidad débil

Analyst view

Analyst sentiment and price target

TMCI

Analyst sentiment

Based on 9 analyst votes · 2026-09-05

56/100

Neutral

Bullish

Hold

Bearish

Precio objetivo

2026-08-09

Bajo

$3.00

Promedio

$8.60

Mediana

$6.50

Alto

$16.00

Resumen de la compañía

IPO: 4/23/2021

Industria: Medical - Devices

P/B i: 4.62

Deuda / Patrimonio i: 0.16

Margen operativo: -25.46%

Margen neto: -27.74%

ROE i: -

ROIC: -

Salud financiera

Puntaje15 / 20

Deuda / Patrimonio: 0.16

Ratio corriente: 4.31

Ratio rápido: 3.13

Estado: Good

Transacciones internas

Actividad reciente de ejecutivos e insiders

Treace John T.

Transacción: 06/11/2026

COMPRA

Cambio

+9,891

Precio

$4.04

Presentación

06/12/2026

Tipo

COMPRA

Treace John T.

Transacción: 06/10/2026

COMPRA

Cambio

+14,715

Precio

$4.02

Presentación

06/12/2026

Tipo

COMPRA

Treace John T.

Transacción: 06/11/2026

COMPRA

Cambio

+22,887

Precio

$4.04

Presentación

06/11/2026

Tipo

COMPRA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
Treace John T.	COMPRA	+9,891	$4.04	06/11/2026	06/12/2026
Treace John T.	COMPRA	+14,715	$4.02	06/10/2026	06/12/2026
Treace John T.	COMPRA	+22,887	$4.04	06/11/2026	06/11/2026
Treace John T.	COMPRA	+29,430	$4.02	06/10/2026	06/11/2026
Treace John T.	COMPRA	+50,000	$3.56	06/01/2026	06/01/2026
Treace John T.	COMPRA	+61,202	$3.02	05/28/2026	05/28/2026
Treace John T.	COMPRA	+49,810	$2.87	05/27/2026	05/28/2026
Treace John T.	COMPRA	+4,508	$2.79	05/26/2026	05/28/2026
Hanna Betsy	COMPRA	+30,000	Not reported	05/19/2026	05/19/2026
HAMILTON LAWRENCE W	COMPRA	+30,000	Not reported	05/19/2026	05/19/2026
Jain Deepti	COMPRA	+30,000	Not reported	05/19/2026	05/19/2026
Berry Lance A	COMPRA	+30,000	Not reported	05/19/2026	05/19/2026
Kiernan Jane E	COMPRA	+30,000	Not reported	05/19/2026	05/19/2026
BAKEWELL JOHN K	COMPRA	+30,000	Not reported	05/19/2026	05/19/2026
Treace John T.	COMPRA	+61,750	$2.62	05/14/2026	05/14/2026
Treace John T.	COMPRA	+49,013	$2.46	05/13/2026	05/14/2026
Treace John T.	COMPRA	+43,000	$2.17	05/12/2026	05/14/2026
Hair Mark	VENTA	-11,547	Not reported	04/17/2026	04/20/2026
Hair Mark	COMPRA	+100,000	Not reported	04/01/2026	04/03/2026
Hair Mark	VENTA	-3,695	Not reported	03/10/2026	03/11/2026

Sobre la compañía

Treace Medical Concepts, Inc.

Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty System, enables surgeons to correct all three dimensions of the bunion deformity, stabilize the first TMT joint, and allow return to weight-bearing in a walking boot; minimally invasive products for four bunion classes; Nanoplasty 3D Minimally Invasive Bunion Correction System delivers a reproducible 3D correction of the bunion deformity through a cosmetically appealing; and Percuplasty Percutaneous 3D Bunion Correction System that provides 3D correction of the bunion deformity through percutaneous incisions. It also provides Adductoplasty System, a system designed for the correction of metatarsus adductus deformities and osteoarthritis of the midfoot; SpeedMTP Rapid Compression Implant; SpeedPlate Implant Fixation Platform to address the fusion of larger bones of the midfoot and rearfoot; SpeedPlate Micro-Quad implant, an implant designed for stability and fit in small incision surgical approaches; and SpeedAkin Anatomic Compression Implant. In addition, the company offers The IntelliGuide patient specific instrumentation provides patient-specific, 3D-printed cut guides, and a pre-operative plan for a complete picture of the deformity and correction. Further, it provides FastGrafter Autografter Harvesting System; SpeedRelease Guided Release Instrument; TriTome Triple-Edge Release Instrument; RazorTome 7mm Precision Osteotome; LapiTome Hooked Bone Removal Osteotome; GreatRelease Rapid MTP Release Instrument; CornerChisel Release Tool; NanoRasp MIS Bone Contouring Tool; FeatherRasp Rapid Bone Contouring Instrument; and Akinator Single-cut Akin Wedge Osteotomy tool. Additionally, the company offers biologics and wedges, such as Treace Allograft Wedges; and CortiFuse Flowable Cortical Fibers. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.

Fuente - Link

Competidores

BVS CBLL EHAB EOLS KIDS LAB RXST SMLR SRDX TOI

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

Treace Medical Concepts, Inc. (TMCI) Q2 2026 Earnings Call Transcript

Seeking Alpha

Treace Medical Concepts Q2 Earnings Call Highlights

Treace Medical Concepts NASDAQ: TMCI reported second-quarter 2026 revenue of $45.4 million, down 4% from the prior-year period, as lower procedure-kit sales to stocking distributors and a continued shift toward lower-priced minimally invasive products weighed on reported sales.

MarketBeat

Treace Medical Concepts (TMCI) Reports Q2 Loss, Tops Revenue Estimates

Treace Medical Concepts (TMCI) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $0.28 per share a year ago.

Zacks Investment Research

Treace Medical Concepts Reports Second Quarter 2026 Financial Results

PONTE VEDRA, Fla., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related deformities, today reported financial results for the second quarter ended June 30, 2026.

GlobeNewsWire

Did Treace Medical Concepts, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

PRNewsWire

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-05-08	-0.31	-0.28	0.03
2026-02-27	-0.1519	-0.12	0.0319
2025-11-06	-0.28	-0.26	0.02
2025-08-07	-0.29	-0.28	0.01
2025-05-08	-0.31	-0.25	0.06
2025-02-27	-0.04	-0.01	0.03
2024-11-05	-0.27	-0.25	0.02
2024-08-06	-0.29	-0.34	-0.05
2024-05-07	-0.3	-0.3	0
2024-02-27	-0.09	-0.1	-0.01
2023-11-09	-0.26	-0.28	-0.02
2023-08-08	-0.23	-0.2	0.03